On July 31, 2025, Jiao Mingming, General Manager of Zhejiang Tianyuan Biotechnology, led a team of company scientists on a visit to the Ningbo Clinical Pathology Diagnosis Center for exchange and collaboration. Director Zhang Zhe and his team warmly received the delegation, and the two sides engaged in in-depth discussions on prospects for scientific research cooperation.

At the beginning of the meeting, Director Zhang Zhe delivered a welcome speech and introduced the attending members of the center. The Ningbo Clinical Pathology Diagnosis Center is the first regional clinical pathology diagnosis center in China, jointly established by the Ningbo Municipal Health Commission and Fudan University Shanghai Cancer Hospital. Its primary responsibilities include conducting clinical pathology diagnoses for municipal medical institutions in Ningbo, guiding city-wide clinical pathology diagnostic services, and organizing continuing education and professional training in clinical pathology diagnostics. General Manager Jiao Mingming expressed sincere gratitude for the strong support from Director Zhang and his team, stating that this visit aimed to leverage the strengths of both parties, identify areas of synergy, and introduce Tianyuan Biotechnology’s corporate development history, core technological advantages, scientific research service platforms, and product development services.

Subsequently, Dr. Chen Junjie, Technology Director of Zhejiang Tianyuan Biotechnology—a Ph.D. from the University of Oxford and postdoctoral fellow at Harvard Medical School—shared the application prospects of Tianyuan’s leading iPS-derived organoid technology in cancer treatment. Dr. Liu Guangcheng, Head of the Cell Laboratory, introduced the company’s self-built HLA-matched umbilical cord mesenchymal stem cell bank—the first of its kind in China. Under the guidance of the National Health Commission (NHC) Research Institute, the company is the sole standard-setting unit for the "Immune Function Assessment Methodology" group standard and has pioneered co-culture technology for building cancer cell banks.

Deputy Director Liu Yiyu, Directors Zhao Ming and Pan Deng, and Section Chief Zhang Jin of the Pathology Center spoke on research needs such as tumor genetic testing, primary cell culture, biobank construction, and exosome applications. Both sides agreed that by leveraging their respective regional strengths and integrating resources, they possess broad potential for collaboration.

Following the seminar, Section Chief Zhang Jin guided the Tianyuan team on a tour of the center’s laboratories, including those for tissue sectioning, cytopathology, molecular pathology, and digital pathology. Director Yao Jincheng and Section Chief Zhang Jin engaged in detailed discussions on tumor genetic testing processes, quality control, and information management.

This exchange laid a solid foundation for future collaboration, exploring cooperation in immunity assessment applications, immune cell storage, cancer cell bank development, and medical testing. To date, the Ningbo Clinical Pathology Diagnosis Center remains China’s only government-established, independently operated, regionally focused pathology diagnosis center, offering unique advantages. Zhejiang Tianyuan Biotechnology has consistently invested in technology for years, establishing itself as a leading enterprise in the cell technology field in Ningbo. The two parties will deepen exchanges to jointly advance precision medical diagnostics and bring new hope to cancer patients.

Background Information Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell R&D, production, operations, and services. It possesses valuable resource banks such as the HLA umbilical cord matching bank, iPS seed cell bank, and cancer cell bank. The company is the standard-setting unit for the NHC’s "Immune Function Assessment Methodology" group standard. It has co-established the Metabolic Immune Monitoring Joint Laboratory with the NHC Research Institute and serves as the Ningbo Storage Center for the National Stem Cell Transformation Resource Bank and the NHC Research Institute’s Achievement Transformation Center.